25 XP   0   0   10

Faron Pharmaceuticals Oy
Buy, Hold or Sell?

Let's analyse Faron together

PenkeI guess you are interested in Faron Pharmaceuticals Oy. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Faron Pharmaceuticals Oy. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Faron Pharmaceuticals Oy

I send you an email if I find something interesting about Faron Pharmaceuticals Oy.

Quick analysis of Faron (30 sec.)










What can you expect buying and holding a share of Faron? (30 sec.)

How much money do you get?

How much money do you get?
p0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
p-14.27
Expected worth in 1 year
p-85.88
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
p-71.61
Return On Investment
-60.9%

For what price can you sell your share?

Current Price per Share
p117.50
Expected price per share
p0 - p120.00
How sure are you?
50%

1. Valuation of Faron (5 min.)




Live pricePrice per Share (EOD)

p117.50

Intrinsic Value Per Share

p-374.48 - p-194.65

Total Value Per Share

p-388.76 - p-208.92

2. Growth of Faron (5 min.)




Is Faron growing?

Current yearPrevious yearGrowGrow %
How rich?-$12.2m$3.1m-$15.3m-125.4%

How much money is Faron making?

Current yearPrevious yearGrowGrow %
Making money-$31.9m-$22.5m-$9.4m-29.4%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Faron (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

What can you expect buying and holding a share of Faron? (5 min.)

Welcome investor! Faron's management wants to use your money to grow the business. In return you get a share of Faron.

What can you expect buying and holding a share of Faron?

First you should know what it really means to hold a share of Faron. And how you can make/lose money.

Speculation

The Price per Share of Faron is p117.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Faron.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Faron, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is p-14.27. Based on the TTM, the Book Value Change Per Share is p-17.90 per quarter. Based on the YOY, the Book Value Change Per Share is p5.93 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is p0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Faron.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 p% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Share
Usd Eps-0.44-0.4%-0.44-0.4%-0.33-0.3%-0.31-0.3%-0.22-0.2%
Usd Book Value Change Per Share-0.22-0.2%-0.22-0.2%0.070.1%-0.050.0%-0.020.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.22-0.2%-0.22-0.2%0.070.1%-0.050.0%-0.020.0%
Usd Price Per Share3.73-3.73-3.36-2.86-3.06-
Price to Earnings Ratio-8.40--8.40--10.24--9.82--13.25-
Price-to-Total Gains Ratio-16.76--16.76-45.54-25.64--85.66-
Price to Book Ratio-21.02--21.02-74.39-38.47-36.51-
Price-to-Total Gains Ratio-16.76--16.76-45.54-25.64--85.66-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.46123
Number of shares684
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.22-0.05
Usd Total Gains Per Share-0.22-0.05
Gains per Quarter (684 shares)-152.28-34.32
Gains per Year (684 shares)-609.14-137.27
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-609-6190-137-147
20-1218-12280-275-284
30-1827-18370-412-421
40-2437-24460-549-558
50-3046-30550-686-695
60-3655-36640-824-832
70-4264-42730-961-969
80-4873-48820-1098-1106
90-5482-54910-1235-1243
100-6091-61000-1373-1380

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.011.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%3.07.00.030.0%3.08.00.027.3%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.011.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%3.07.00.030.0%3.08.00.027.3%

Fundamentals of Faron

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. It also develops Haematokine, an investigational AOC3 inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. In addition, the company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Fundamental data was last updated by Penke on 2024-03-30 22:19:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Faron Pharmaceuticals Oy.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Faron earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare Faron to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that 0.00 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Faron Pharmaceuticals Oy:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-21,143.2%+21,143.2%
5Y-21,143.2%10Y-10,861.4%-10,281.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--199.6%+199.6%
TTM--213.0%+213.0%
YOY--279.3%+279.3%
5Y-21,143.2%-438.4%-20,704.8%
10Y-10,861.4%-605.5%-10,255.9%
1.1.2. Return on Assets

Shows how efficient Faron is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Faron to the Biotechnology industry mean.
  • -266.5% Return on Assets means that Faron generated -2.66 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Faron Pharmaceuticals Oy:

  • The MRQ is -266.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -266.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-266.5%TTM-266.5%0.0%
TTM-266.5%YOY-160.8%-105.7%
TTM-266.5%5Y-202.1%-64.3%
5Y-202.1%10Y-137.8%-64.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-266.5%-13.5%-253.0%
TTM-266.5%-12.9%-253.6%
YOY-160.8%-11.8%-149.0%
5Y-202.1%-14.1%-188.0%
10Y-137.8%-16.0%-121.8%
1.1.3. Return on Equity

Shows how efficient Faron is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Faron to the Biotechnology industry mean.
  • 0.0% Return on Equity means Faron generated 0.00 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Faron Pharmaceuticals Oy:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-726.3%+726.3%
TTM-5Y-1,398.7%+1,398.7%
5Y-1,398.7%10Y-757.8%-640.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM--16.1%+16.1%
YOY-726.3%-15.1%-711.2%
5Y-1,398.7%-19.9%-1,378.8%
10Y-757.8%-20.9%-736.9%

1.2. Operating Efficiency of Faron Pharmaceuticals Oy.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Faron is operating .

  • Measures how much profit Faron makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Faron to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated 0.00  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Faron Pharmaceuticals Oy:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-21,013.7%+21,013.7%
5Y-21,013.7%10Y-10,779.9%-10,233.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--295.1%+295.1%
TTM--225.8%+225.8%
YOY--288.4%+288.4%
5Y-21,013.7%-477.4%-20,536.3%
10Y-10,779.9%-625.6%-10,154.3%
1.2.2. Operating Ratio

Measures how efficient Faron is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are 0.00 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of Faron Pharmaceuticals Oy:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y206.947-206.947
5Y206.94710Y106.517+100.430
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.090-3.090
TTM-3.264-3.264
YOY-3.783-3.783
5Y206.9475.679+201.268
10Y106.5177.894+98.623

1.3. Liquidity of Faron Pharmaceuticals Oy.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Faron is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.93 means the company has 0.93 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of Faron Pharmaceuticals Oy:

  • The MRQ is 0.929. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.929. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.929TTM0.9290.000
TTM0.929YOY1.675-0.746
TTM0.9295Y1.288-0.359
5Y1.28810Y1.934-0.646
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9293.914-2.985
TTM0.9294.220-3.291
YOY1.6755.388-3.713
5Y1.2886.045-4.757
10Y1.9346.406-4.472
1.3.2. Quick Ratio

Measures if Faron is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Faron to the Biotechnology industry mean.
  • A Quick Ratio of 0.75 means the company can pay off 0.75 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Faron Pharmaceuticals Oy:

  • The MRQ is 0.754. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.754. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.754TTM0.7540.000
TTM0.754YOY1.152-0.398
TTM0.7545Y0.995-0.241
5Y0.99510Y0.976+0.019
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7543.572-2.818
TTM0.7543.998-3.244
YOY1.1525.390-4.238
5Y0.9955.969-4.974
10Y0.9766.287-5.311

1.4. Solvency of Faron Pharmaceuticals Oy.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Faron assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Faron to Biotechnology industry mean.
  • A Debt to Asset Ratio of 2.02 means that Faron assets are financed with 201.8% credit (debt) and the remaining percentage (100% - 201.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Faron Pharmaceuticals Oy:

  • The MRQ is 2.018. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 2.018. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ2.018TTM2.0180.000
TTM2.018YOY0.779+1.240
TTM2.0185Y1.163+0.855
5Y1.16310Y1.008+0.154
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0180.336+1.682
TTM2.0180.334+1.684
YOY0.7790.269+0.510
5Y1.1630.366+0.797
10Y1.0080.390+0.618
1.4.2. Debt to Equity Ratio

Measures if Faron is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Faron to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has 0.00 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Faron Pharmaceuticals Oy:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY3.517-3.517
TTM-5Y5.909-5.909
5Y5.90910Y3.260+2.649
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.382-0.382
TTM-0.396-0.396
YOY3.5170.335+3.182
5Y5.9090.434+5.475
10Y3.2600.465+2.795

2. Market Valuation of Faron Pharmaceuticals Oy

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings Faron generates.

  • Above 15 is considered overpriced but always compare Faron to the Biotechnology industry mean.
  • A PE ratio of -8.40 means the investor is paying -8.40 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Faron Pharmaceuticals Oy:

  • The EOD is -3.288. Based on the earnings, the company is expensive. -2
  • The MRQ is -8.396. Based on the earnings, the company is expensive. -2
  • The TTM is -8.396. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.288MRQ-8.396+5.107
MRQ-8.396TTM-8.3960.000
TTM-8.396YOY-10.243+1.847
TTM-8.3965Y-9.822+1.426
5Y-9.82210Y-13.250+3.428
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.288-2.259-1.029
MRQ-8.396-2.569-5.827
TTM-8.396-2.664-5.732
YOY-10.243-4.120-6.123
5Y-9.822-6.258-3.564
10Y-13.250-6.171-7.079
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Faron Pharmaceuticals Oy:

  • The EOD is -4.041. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -10.318. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.318. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.041MRQ-10.318+6.276
MRQ-10.318TTM-10.3180.000
TTM-10.318YOY-9.566-0.751
TTM-10.3185Y-10.410+0.092
5Y-10.41010Y-13.899+3.489
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.041-2.924-1.117
MRQ-10.318-3.246-7.072
TTM-10.318-3.488-6.830
YOY-9.566-5.620-3.946
5Y-10.410-8.315-2.095
10Y-13.899-8.826-5.073
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Faron is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -21.02 means the investor is paying -21.02 for each 1 in book value.

Let's take a look of the Price to Book Ratio trends of Faron Pharmaceuticals Oy:

  • The EOD is -8.232. Based on the equity, the company is expensive. -2
  • The MRQ is -21.018. Based on the equity, the company is expensive. -2
  • The TTM is -21.018. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.232MRQ-21.018+12.786
MRQ-21.018TTM-21.0180.000
TTM-21.018YOY74.394-95.412
TTM-21.0185Y38.467-59.485
5Y38.46710Y36.515+1.953
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.2321.851-10.083
MRQ-21.0182.090-23.108
TTM-21.0182.095-23.113
YOY74.3942.844+71.550
5Y38.4673.466+35.001
10Y36.5153.815+32.700
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Faron Pharmaceuticals Oy compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---17.903-17.9030%5.929-402%-4.035-77%-1.323-93%
Book Value Per Share---14.273-14.2730%3.629-493%-2.096-85%2.020-807%
Current Ratio--0.9290.9290%1.675-45%1.288-28%1.934-52%
Debt To Asset Ratio--2.0182.0180%0.779+159%1.163+74%1.008+100%
Debt To Equity Ratio----0%3.517-100%5.909-100%3.260-100%
Dividend Per Share----0%-0%-0%-0%
Eps---35.733-35.7330%-26.360-26%-24.930-30%-17.472-51%
Free Cash Flow Per Share---29.077-29.0770%-28.224-3%-23.914-18%-16.389-44%
Free Cash Flow To Equity Per Share--0.1240.1240%3.604-97%-0.530+526%0.929-87%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---194.649--------
Intrinsic Value_10Y_min---374.483--------
Intrinsic Value_1Y_max---17.100--------
Intrinsic Value_1Y_min---29.509--------
Intrinsic Value_3Y_max---53.211--------
Intrinsic Value_3Y_min---96.130--------
Intrinsic Value_5Y_max---91.533--------
Intrinsic Value_5Y_min---170.428--------
Market Cap8084846000.000-155%20642160000.00020642160000.0000%18577944000.000+11%15798133120.000+31%16912809760.000+22%
Net Profit Margin----0%-0%-211.4320%-108.6140%
Operating Margin----0%-0%-210.1370%-107.7990%
Operating Ratio----0%-0%206.947-100%106.517-100%
Pb Ratio-8.232+61%-21.018-21.0180%74.394-128%38.467-155%36.515-158%
Pe Ratio-3.288+61%-8.396-8.3960%-10.243+22%-9.822+17%-13.250+58%
Price Per Share117.500-155%300.000300.0000%270.000+11%229.600+31%245.800+22%
Price To Free Cash Flow Ratio-4.041+61%-10.318-10.3180%-9.566-7%-10.410+1%-13.899+35%
Price To Total Gains Ratio-6.563+61%-16.757-16.7570%45.539-137%25.642-165%-85.663+411%
Quick Ratio--0.7540.7540%1.152-35%0.995-24%0.976-23%
Return On Assets---2.665-2.6650%-1.608-40%-2.021-24%-1.378-48%
Return On Equity----0%-7.2630%-13.9870%-7.5780%
Total Gains Per Share---17.903-17.9030%5.929-402%-4.035-77%-1.323-93%
Usd Book Value---12213595.571-12213595.5710%3105548.264-493%-1793938.367-85%1728379.157-807%
Usd Book Value Change Per Share---0.223-0.2230%0.074-402%-0.050-77%-0.016-93%
Usd Book Value Per Share---0.178-0.1780%0.045-493%-0.026-85%0.025-807%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.444-0.4440%-0.328-26%-0.310-30%-0.217-51%
Usd Free Cash Flow---24880571.389-24880571.3890%-24150480.193-3%-20462561.809-18%-14024243.022-44%
Usd Free Cash Flow Per Share---0.362-0.3620%-0.351-3%-0.297-18%-0.204-44%
Usd Free Cash Flow To Equity Per Share--0.0020.0020%0.045-97%-0.007+526%0.012-87%
Usd Market Cap100543144.856-155%256705901.760256705901.7600%231035311.584+11%196465583.480+31%210327702.175+22%
Usd Price Per Share1.461-155%3.7313.7310%3.358+11%2.855+31%3.057+22%
Usd Profit---31964371.678-31964371.6780%-22556199.419-29%-21609422.265-32%-14999542.689-53%
Usd Revenue----0%-0%4044.237-100%297889.979-100%
Usd Total Gains Per Share---0.223-0.2230%0.074-402%-0.050-77%-0.016-93%
 EOD+2 -6MRQTTM+0 -0YOY+6 -225Y+8 -2210Y+7 -23

3.2. Fundamental Score

Let's check the fundamental score of Faron Pharmaceuticals Oy based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.288
Price to Book Ratio (EOD)Between0-1-8.232
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.754
Current Ratio (MRQ)Greater than10.929
Debt to Asset Ratio (MRQ)Less than12.018
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-2.665
Total1/10 (10.0%)

3.3. Technical Score

Let's check the technical score of Faron Pharmaceuticals Oy based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.330
Ma 20Greater thanMa 50133.475
Ma 50Greater thanMa 100157.370
Ma 100Greater thanMa 200226.605
OpenGreater thanClose117.500
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Other Current Assets  236,030-235,84618496279163442-528-86
Net Debt  -165,597-197,005-362,602287,035-75,567-207,360-282,927820,284537,357
Net Working Capital  92,426175,353267,780-193,49674,283340,352414,635-478,050-63,415



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets11,271
Total Liabilities22,747
Total Stockholder Equity-11,476
 As reported
Total Liabilities 22,747
Total Stockholder Equity+ -11,476
Total Assets = 11,271

Assets

Total Assets11,271
Total Current Assets9,730
Long-term Assets1,541
Total Current Assets
Cash And Cash Equivalents 6,990
Net Receivables 905
Total Current Assets  (as reported)9,730
Total Current Assets  (calculated)7,895
+/- 1,835
Long-term Assets
Property Plant Equipment 327
Intangible Assets 1,154
Other Assets 60
Long-term Assets  (as reported)1,541
Long-term Assets  (calculated)1,541
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities10,471
Long-term Liabilities12,276
Total Stockholder Equity-11,476
Total Current Liabilities
Short-term Debt 2,004
Short Long Term Debt 1,851
Accounts payable 6,014
Other Current Liabilities 2,453
Total Current Liabilities  (as reported)10,471
Total Current Liabilities  (calculated)12,322
+/- 1,851
Long-term Liabilities
Long term Debt 11,102
Capital Lease Obligations Min Short Term Debt-1,688
Other Liabilities 1,011
Long-term Liabilities Other 853
Long-term Liabilities  (as reported)12,276
Long-term Liabilities  (calculated)11,278
+/- 998
Total Stockholder Equity
Common Stock2,691
Retained Earnings -143,713
Other Stockholders Equity 129,546
Total Stockholder Equity (as reported)-11,476
Total Stockholder Equity (calculated)-11,476
+/-0
Other
Capital Stock2,691
Cash and Short Term Investments 6,990
Common Stock Shares Outstanding 50,724
Liabilities and Stockholders Equity 11,271
Net Debt 6,279
Net Invested Capital 1,477
Net Tangible Assets -12,630
Net Working Capital -741
Property Plant and Equipment Gross 327
Short Long Term Debt Total 13,269



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
> Total Assets 
1,936
2,237
2,165
14,821
17,287
14,887
8,002
10,209
8,367
13,182
11,271
11,27113,1828,36710,2098,00214,88717,28714,8212,1652,2371,936
   > Total Current Assets 
860
1,144
981
13,791
16,333
13,230
6,825
9,204
7,371
12,023
9,730
9,73012,0237,3719,2046,82513,23016,33313,7919811,144860
       Cash And Cash Equivalents 
0
0
242
11,068
11,478
9,310
4,067
7,059
4,108
6,853
6,990
6,9906,8534,1087,0594,0679,31011,47811,06824200
       Net Receivables 
314
45
40
826
1,269
2,326
945
1,250
1,270
1,418
905
9051,4181,2701,2509452,3261,2698264045314
       Inventory 
546
1,099
699
649
1,451
0
0
0
0
0
0
0000001,4516496991,099546
   > Long-term Assets 
1,076
1,093
1,184
1,029
954
1,657
1,177
1,005
996
1,159
1,541
1,5411,1599961,0051,1771,6579541,0291,1841,0931,076
       Property Plant Equipment 
0
0
0
28
21
22
17
399
375
207
327
32720737539917222128000
       Intangible Assets 
1,076
1,093
1,184
1,001
933
325
525
529
565
899
1,154
1,1548995655295253259331,0011,1841,0931,076
       Other Assets 
0
0
0
1
1,475
1,310
635
0
56
53
60
60535606351,3101,4751000
> Total Liabilities 
2,773
3,186
3,353
3,643
6,403
10,144
7,633
8,599
10,216
10,264
22,747
22,74710,26410,2168,5997,63310,1446,4033,6433,3533,1862,773
   > Total Current Liabilities 
952
1,741
1,662
2,197
4,371
8,056
5,745
6,075
6,503
7,178
10,471
10,4717,1786,5036,0755,7458,0564,3712,1971,6621,741952
       Short-term Debt 
0
2,033
1,691
245
93
338
245
298
298
613
2,004
2,004613298298245338932451,6912,0330
       Short Long Term Debt 
0
2,033
1,691
245
93
338
245
163
122
429
1,851
1,851429122163245338932451,6912,0330
       Accounts payable 
89
45
10
436
2,021
3,196
3,534
2,967
4,608
2,229
6,014
6,0142,2294,6082,9673,5343,1962,021436104589
       Other Current Liabilities 
86
1,108
1,652
1,001
1,686
4,522
1,966
2,810
1,597
1,477
2,453
2,4531,4771,5972,8101,9664,5221,6861,0011,6521,10886
   > Long-term Liabilities 
1,821
1,445
1,691
1,446
2,032
2,088
1,888
2,524
3,713
3,086
12,276
12,2763,0863,7132,5241,8882,0882,0321,4461,6911,4451,821
       Long term Debt 
1,821
1,445
1,691
1,446
2,033
2,088
1,887
2,263
2,728
2,918
11,102
11,1022,9182,7282,2631,8872,0882,0331,4461,6911,4451,821
       Capital Lease Obligations Min Short Term Debt
0
-2,033
-1,691
-245
-93
-338
-245
98
77
-413
-1,688
-1,688-4137798-245-338-93-245-1,691-2,0330
       Other Liabilities 
0
0
0
0
614
0
1
0
786
151
1,011
1,0111517860106140000
       Long-term Liabilities Other 
0
0
0
0
-1
0
1
0
786
1
853
8531786010-10000
> Total Stockholder Equity
0
-949
-1,188
11,178
10,884
4,743
369
1,610
-1,849
2,918
-11,476
-11,4762,918-1,8491,6103694,74310,88411,178-1,188-9490
   Common Stock
1,295
1,416
2,691
2,691
2,691
2,691
2,691
2,691
2,691
2,691
2,691
2,6912,6912,6912,6912,6912,6912,6912,6912,6911,4161,295
   Retained Earnings Total Equity00000000000
   Accumulated Other Comprehensive Income 00-30-26-22-14-18-11-2-2-2
   Capital Surplus 00000000000
   Treasury Stock00000000000
   Other Stockholders Equity 
0
6,603
6,453
24,533
32,362
48,590
64,486
78,916
92,017
116,492
129,546
129,546116,49292,01778,91664,48648,59032,36224,5336,4536,6030



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-27,425
Operating Income-27,426-27,425
 
Operating Expense (+$)
Research Development20,730
Selling General Administrative7,498
Selling And Marketing Expenses0
Operating Expense27,42528,228
 
Net Interest Income (+$)
Interest Income11
Interest Expense-1,400
Other Finance Cost-40
Net Interest Income-1,349
 
Pretax Income (+$)
Operating Income-27,426
Net Interest Income-1,349
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-28,730-26,122
EBIT - interestExpense = -28,826
-28,730
-28,634
Interest Expense1,400
Earnings Before Interest and Taxes (EBIT)-27,426-27,330
Earnings Before Interest and Taxes (EBITDA)-27,030
 
After tax Income (+$)
Income Before Tax-28,730
Tax Provision-0
Net Income From Continuing Ops-28,730-28,730
Net Income-30,034
Net Income Applicable To Common Shares-28,730
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses27,425
Total Other Income/Expenses Net-1,3041,349
 

Technical Analysis of Faron
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Faron. The general trend of Faron is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Faron's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Faron Pharmaceuticals Oy.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 120.00 < 120.00 < 120.00.

The bearish price targets are: .

Tweet this
Faron Pharmaceuticals Oy Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Faron Pharmaceuticals Oy. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Faron Pharmaceuticals Oy Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Faron Pharmaceuticals Oy. The current macd is -11.4256649.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Faron price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Faron. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Faron price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Faron Pharmaceuticals Oy Daily Moving Average Convergence/Divergence (MACD) ChartFaron Pharmaceuticals Oy Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Faron Pharmaceuticals Oy. The current adx is 23.72.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Faron shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Faron Pharmaceuticals Oy Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Faron Pharmaceuticals Oy. The current sar is 137.23.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Faron Pharmaceuticals Oy Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Faron Pharmaceuticals Oy. The current rsi is 31.33. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Faron Pharmaceuticals Oy Daily Relative Strength Index (RSI) ChartFaron Pharmaceuticals Oy Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Faron Pharmaceuticals Oy. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Faron price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Faron Pharmaceuticals Oy Daily Stochastic Oscillator ChartFaron Pharmaceuticals Oy Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Faron Pharmaceuticals Oy. The current cci is -146.99751431.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Faron Pharmaceuticals Oy Daily Commodity Channel Index (CCI) ChartFaron Pharmaceuticals Oy Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Faron Pharmaceuticals Oy. The current cmo is -48.23525454.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Faron Pharmaceuticals Oy Daily Chande Momentum Oscillator (CMO) ChartFaron Pharmaceuticals Oy Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Faron Pharmaceuticals Oy. The current willr is -87.83783784.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Faron Pharmaceuticals Oy Daily Williams %R ChartFaron Pharmaceuticals Oy Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Faron Pharmaceuticals Oy.

Faron Pharmaceuticals Oy Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Faron Pharmaceuticals Oy. The current atr is 13.83.

Faron Pharmaceuticals Oy Daily Average True Range (ATR) ChartFaron Pharmaceuticals Oy Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Faron Pharmaceuticals Oy. The current obv is -577,069.

Faron Pharmaceuticals Oy Daily On-Balance Volume (OBV) ChartFaron Pharmaceuticals Oy Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Faron Pharmaceuticals Oy. The current mfi is 20.46.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Faron Pharmaceuticals Oy Daily Money Flow Index (MFI) ChartFaron Pharmaceuticals Oy Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Faron Pharmaceuticals Oy.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-04MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-10MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-21ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Faron Pharmaceuticals Oy Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Faron Pharmaceuticals Oy based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.330
Ma 20Greater thanMa 50133.475
Ma 50Greater thanMa 100157.370
Ma 100Greater thanMa 200226.605
OpenGreater thanClose117.500
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Faron with someone you think should read this too:
  • Are you bullish or bearish on Faron? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Faron? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Faron Pharmaceuticals Oy

I send you an email if I find something interesting about Faron Pharmaceuticals Oy.


Comments

How you think about this?

Leave a comment

Stay informed about Faron Pharmaceuticals Oy.

Receive notifications about Faron Pharmaceuticals Oy in your mailbox!